Videnskabelige Publikationer 2006 - Rigshospitalet

Sorensen PS, Tscherning T, Mathiesen HK, Langkilde AR, Ross C, Ravnborg M, et al. Neutralizing
antibodies hamper IFNbeta bioactivity and treatment effect on MRI in patients with MS. Neurology
2006;67(9):1681-3.
Onkologisk Klinik og Radioterapiklinikken
Disputatser og ph.d.-afhandlinger forsvaret i året
Gronlund, B. Progressive epithelial ovarian carcinoma. Prognostic factors and clinical management
(disputats). Copenhagen: Dan Med Bull; 2006:232-257. Forsvaret den 24/5 2006 ved Københavns
Universitet. Det Sundhedsvidenskabelige Fakultet.
Hutchings, M. FDG-PET and FDG-PET/CT in Hodgkin lymphoma. Diagnostic, prognostic and clinical
value in staging, treatment monitoring and radiotherapy planning. (ph.d.-afhandling). København: Eget
Forlag; 2006:1-44. Forsvaret den 9/6 2006 ved Københavns Universitet, Det Sundhedsvidenskabelige
Fakultet.
A. Førsteforfatter fra forskningsenheden
Andersson M. [Trastuzumab improves adjuvant therapy. The Danish Society of Clinical Oncology].
Ugeskr Laeger 2006;168(12):1229.
Daugaard G, Jorgensen N, Skakkebaek NE. Are men with testicular cancer at risk of developing a
contralateral tumor? Nature Clinical Practice Urology 2006;3:134-5.
Daugaard G, Karas V, Sommer P. Inguinal metastases from testicular cancer. BJU Int
2006;97(4):724-6.
Ejlertsen B, Mouridsen HT, Jensen MB, Bengtsson NO, Bergh J, Cold S, et al. Similar efficacy for
ovarian ablation compared with cyclophosphamide, methotrexate, and fluorouracil: from a randomized
comparison of premenopausal patients with node-positive, hormone receptor-positive breast cancer. J
Clin Oncol 2006;24(31):4956-62.
Enmark M, Korreman S, Nystrom H. IGRT of prostate cancer; is the margin reduction gained from
daily IG time-dependent? Acta Oncol 2006;45(7):907-14.
Gronlund B, Hogdall EV, Christensen IJ, Johansen JS, Norgaard-Pedersen B, Engelholm SA, et al.
Pre-treatment prediction of chemoresistance in second-line chemotherapy of ovarian carcinoma: value
of serological tumor marker determination (tetranectin, YKL-40, CASA, CA 125). Int J Biol Markers
2006;21(3):141-8.
Hutchings M, Loft A, Hansen M, Ralfkiaer E, Specht L. Different histopathological subtypes of Hodgkin
lymphoma show significantly different levels of FDG uptake. Hematol Oncol 2006;24(3):146-50.
Korreman S, Mostafavi H, Le QT, Boyer A. Comparison of respiratory surrogates for gated lung
radiotherapy without internal fiducials. Acta Oncol 2006;45(7):935-42.
Korreman SS, Pedersen AN, Josipovic M, Aarup LR, Juhler-Nottrup T, Specht L, et al. Cardiac and
pulmonary complication probabilities for breast cancer patients after routine end-inspiration gated
radiotherapy. Radiother Oncol 2006;80(2):257-62.
Korreman SS, Pedersen AN, Aarup LR, Nottrup TJ, Specht L, Nystrom H. Reduction of cardiac and
pulmonary complication probabilities after breathing adapted radiotherapy for breast cancer. Int J
Radiat Oncol Biol Phys 2006;65(5):1375-80.
Lajer CB, Specht LK, Kirkegaard J, Homoe P. [Photodynamic therapy for head and neck cancer].
Ugeskr Laeger 2006;168(23):2227-31.
Langer SW, Thougaard AV, Sehested M, Jensen PB. Treatment of anthracycline extravasation in
mice with dexrazoxane with or without DMSO and hydrocortisone. Cancer Chemother Pharmacol
2006;57(1):125-8.
50